Updated on 2022/03/31

写真a

 
KANEMATSU Takeshi
 
Organization
Nagoya University Hospital Department of Clinical Laboratory Assistant professor of hospital
Title
Assistant professor of hospital

Degree 2

  1. Doctor of Philosophy (Medical Science) ( 2022.3   Nagoya University ) 

  2. Bachelor of Medicine ( 2006.3   Nagoya University ) 

Research Areas 3

  1. Others / Others  / 血栓・止血学

  2. Life Science / Hematology and medical oncology

  3. Life Science / Hematology and medical oncology

Research History 1

  1. Nagoya University   Nagoya University Hospital Department of Clinical Laboratory   Assistant professor of hospital

    2018.4

Education 1

  1. Nagoya University   Faculty of Medicine

    2000.4 - 2006.3

      More details

    Country: Japan

Professional Memberships 7

  1. 日本検査血液学会

  2. 日本輸血・細胞治療学会

  3. 日本臨床腫瘍学会

  4. International Society on Thrombosis and Haemostasis

  5. 日本内科学会

  6. 日本血栓止血学会

  7. 日本血液学会

▼display all

 

Papers 32

  1. F9 mRNA splicing aberration due to a deep Intronic structural variation in a patient with moderate hemophilia B. Reviewed International journal

    Odaira K, Kawashima F, Tamura S, Suzuki N, Tokoro M, Hayakawa Y, Suzuki A, Kanematsu T, Okamoto S, Takagi A, Katsumi A, Matsushita T, Shima M, Nogami K, Kojima T, Hayakawa F

    Thrombosis research   Vol. 213   page: 91 - 96   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Thrombosis Research  

    Introduction: Hemophilia B (HB) is a hereditary bleeding disorder caused by the genetic variation of the coagulation factor IX (FIX) gene (F9). Several F9 structural abnormalities, including large deletion and/or insertion, have been observed to cause HB development. However, there is limited information available on F9 deep intronic variations. In this study, we report about a novel large deletion/insertion observed in a deep region of F9 intron 1 that causes mRNA splicing abnormalities. Patient and methods: The patient was a Japanese male diagnosed with moderate HB (FIX:C = 3.0 IU/dL). The genomic DNA of the patient was isolated from peripheral blood leukocytes. DNA sequences of F9 exons and splice donor/acceptor sites were analyzed via polymerase chain reaction and Sanger sequencing. Variant-affected F9 mRNA aberration and FIX protein production, secretion, and coagulant activity were analyzed by cell-based exon trap and splicing-competent FIX expression vector systems. Results: A 28-bp deletion/476-bp insertion was identified in the F9 intron 1 of a patient with moderate HB. A DNA sequence identical to a part of the inverted HNRNPA1 exon 12 was inserted. Cell-based transcript analysis revealed that this large intronic deletion/insertion disrupted F9 mRNA splicing pattern, resulting in reduction of protein-coding F9 mRNA. Conclusion: A novel deep intronic F9 rearrangement was identified in a Japanese patient with moderate HB. Abnormal F9 mRNA splicing pattern due to this deep intronic structural variation resulted in a reduction of protein-coding F9 mRNA, which probably caused the moderate HB phenotype.

    DOI: 10.1016/j.thromres.2022.03.010

    Scopus

    PubMed

  2. Periosteum-derived podoplanin-expressing stromal cells regulate nascent vascularization during epiphyseal marrow development. Reviewed International journal

    Tamura S, Mukaide M, Katsuragi Y, Fujii W, Odaira K, Suzuki N, Tsukiji N, Okamoto S, Suzuki A, Kanematsu T, Katsumi A, Takagi A, Ikeda K, Ueyama J, Hirayama M, Suzuki-Inoue K, Matsushita T, Kojima T, Hayakawa F

    The Journal of biological chemistry     page: 101833   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jbc.2022.101833

    PubMed

  3. Protein S-Leu17Pro disrupts the hydrophobicity of its signal peptide causing a proteasome-dependent degradation. Reviewed International journal

    Okada K, Tamura S, Suzuki N, Odaira K, Mukaide M, Fujii W, Katsuragi Y, Suzuki A, Kanematsu T, Okamoto S, Suzuki N, Katsumi A, Matsushita T, Kojima T, Hayakawa F

    Thrombosis research   Vol. 210   page: 26 - 32   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Thrombosis Research  

    Introduction: Protein S is a vitamin K-dependent glycoprotein with important anticoagulant, fibrinolytic, anti-inflammatory, anti-apoptotic, and cytoprotective functions. Congenital protein S deficiency is an autosomal dominant thrombophilia due to protein S gene (PROS1) variations. Our group identified a variation in PROS1 that translates into protein S deficiency: c.50 T > C (p.Leu17Pro). Here, we investigated the mechanisms by which this variation results in protein S deficiency. Materials and methods: The effect of L17P substitution on protein S signal peptide was predicted by in silico (a computational prediction technique) analysis of hydrophobicity and signal peptide cleavage. Recombinant protein S was overexpressed in HEK293 and COS-7 cells. Intracellular kinetics and extracellular secretion of recombinant protein S-L17P were analyzed by western blotting and immunocytochemistry. Results: In silico hydrophobicity analysis showed that protein S-L17P had disrupted hydrophobic status in the h-region of its signal peptide. Under normal culture conditions, recombinant protein S -L17P was not detected in either transfectant cell lysates or medium. Upon treatment with a proteasome inhibitor, recombinant protein S-L17P was clearly detected in the cell lysate, but not in the culture medium. Recombinant protein S-L17P did not undergo post-translational modification with N-glycosylation, suggesting that the nascent polypeptide of recombinant protein S-L17P is not transported to the endoplasmic reticulum lumen, but is mislocalized to the cytosol. Conclusion: PROS1-L17P variation translates into protein S deficiency. Protein S-L17P causes its cytosolic mislocalization resulting in its proteasome-dependent degradation.

    DOI: 10.1016/j.thromres.2021.12.014

    Scopus

    PubMed

  4. Development and validation of a novel qualitative test for plasma fibrinogen utilizing clot waveform analysis Reviewed International journal

    Suzuki Atsuo, Suzuki Nobuaki, Kanematsu Takeshi, Shinohara Sho, Kurono Hiroshi, Arai Nobuo, Okamoto Shuichi, Suzuki Naruko, Tamura Shogo, Kikuchi Ryosuke, Katsumi Akira, Kojima Tetsuhito, Matsushita Tadashi

    SCIENTIFIC REPORTS   Vol. 12 ( 1 ) page: 434   2022.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Scientific Reports  

    Plasma fibrinogen is commonly examined by Clauss fibrinogen assay, which cannot distinguish between quantitative and qualitative fibrinogen anomalies. However, our previously reported Clauss fibrinogen assay utilizing clot waveform analysis (Clauss-CWA) provides additional information that contributes to the classification of fibrinogen anomalies. In this study, we adopted the Clauss-CWA method for an autoanalyzer to automatically measure the antigenic estimate (eAg) of fibrinogen in addition to the functional amount (Ac), and to thus provide the Ac/eAg ratio as a qualitative indicator. Performance was validated by receiver operating characteristics (ROC) and precision recall (PR) curve analyses using a patient cohort, consisting of a training cohort (n = 519) and a validation cohort (n = 523), both of which contained cases of congenital (hypo)dysfibrinogenemia as qualitative defects. We obtained an optimal cutoff of 0.65 for Ac/eAg by ROC curve analysis of the training cohort, offering superior sensitivity (> 0.9661) and specificity (1.000). This cutoff was validated in the validation cohort, providing positive predictive value > 0.933 and negative predictive value > 0.998. PR curve analysis also showed that Clauss-CWA provided excellent performance for detecting qualitative fibrinogen anomalies. The Clauss-CWA method may represent a useful approach for detecting qualitative fibrinogen abnormalities in routine laboratory testing.

    DOI: 10.1038/s41598-021-04464-5

    Web of Science

    Scopus

    PubMed

  5. The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophilia HCC after HCV eradication in hemophilia Reviewed International journal

    Inukai Yosuke, Imai Norihiro, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Okamoto Shuichi, Kanematsu Takeshi, Suzuki Nobuaki, Matsushita Tadashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

    ANNALS OF HEPATOLOGY   Vol. 27 ( 1 ) page: 100545   2022

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Annals of Hepatology  

    Introduction and objectives: Hepatitis C virus (HCV) infections in patients with hemophilia lead to the development of hepatocellular carcinoma (HCC) at a relatively younger age than that in patients without hemophilia. Although recent progress in direct-acting-antivirals has facilitated a high rate of sustained virological response (SVR), the clinical influence of HCV eradication in hemophilia patients remains unclear. This study aimed to compare the clinical outcomes of SVR against HCV in patients with and without hemophilia. Patients and methods: The study enrolled 699 patients who achieved SVR after HCV antiviral treatment. Patients were divided into two groups: 78 patients with hemophilia (H group) and 621 patients without hemophilia (NH group). We evaluated patient characteristics, clinical outcomes, and the cumulative incidence of HCC after SVR. Results: Compared with the NH group, patients in the H-group were significantly younger and had a lower hepatic fibrosis score. No difference was found in the incidence of liver-related disease or overall death between the two groups over a mean follow-up period of 7 years. Four patients in the H group and 36 patients in the NH group were diagnosed with HCC after SVR. Multivariate analysis showed that male sex, age, and cirrhosis were significant risk factors for HCC incidence. There was no significant difference in the cumulative incidence of HCC after propensity-score matching adjusting for the risk factors of HCC between the two groups. Conclusion: Hemophilia is not a significant risk factor for hepatocarcinogenesis after SVR against HCV.

    DOI: 10.1016/j.aohep.2021.100545

    Web of Science

    Scopus

    PubMed

  6. Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs Reviewed International journal

    Yamamoto Takafumi, Imai Norihiro, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Okamoto Shuichi, Kanematsu Takeshi, Suzuki Nobuaki, Matsushita Tadashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

    ANTICANCER RESEARCH   Vol. 41 ( 5 ) page: 2569 - 2573   2021.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Anticancer Research  

    Background: Hepatocellular carcinoma (HCC) is considered a leading cause of death in patients with haemophilia. Recent advances in the treatment of unresectable HCC with molecular-Targeted agents (MTAs) have led to better clinical outcomes. However, the tolerability of MTAs by haemophilic patients with HCC remains unclear. Aim: This study aimed to compare the tolerability of MTAs in such patients. Patients and Methods: From January 2011 to October 2020, five haemophilic patients with HCC were treated with MTAs. Adverse events were assessed in comparison with 265 non-haemophilic patients with HCC. Results: The prevalence of hand foot skin reaction was not higher in the haemophiliacs than in the non-haemophiliacs, whereas the rate of haemorrhagic events was higher in the haemophiliacs (6.0% versus 40.0%, p=0.037). Conclusion: Haemophiliacs tolerate long-Term MTA use, without the occurrence of life-Threatening complications. However, careful observation and prevention are needed for MTA-related gastrointestinal bleeding in haemophiliacs.

    DOI: 10.21873/anticanres.15035

    Web of Science

    Scopus

    PubMed

  7. Essential role of a carboxyl-terminal alpha-helix motif in the secretion of coagulation factor XI Reviewed International journal

    Hayakawa Yuri, Tamura Shogo, Suzuki Nobuaki, Odaira Koya, Tokoro Mahiru, Kawashima Fumika, Hayakawa Fumihiko, Takagi Akira, Katsumi Akira, Suzuki Atsuo, Okamoto Shuichi, Kanematsu Takeshi, Matsushita Tadashi, Kojima Tetsuhito

    JOURNAL OF THROMBOSIS AND HAEMOSTASIS   Vol. 19 ( 4 ) page: 920 - 930   2021.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Journal of Thrombosis and Haemostasis  

    Background: Coagulation factor XI (FXI) is a plasma serine protease zymogen that contributes to hemostasis. However, the mechanism of its secretion remains unclear. Objective: To determine the molecular mechanism of FXI secretion by characterizing a novel FXI mutant identified in a FXI-deficient Japanese patient. Patient/Methods: The FXI gene (F11) was analyzed by direct sequencing. Mutant recombinant FXI (rFXI) was overexpressed in HEK293 or COS-7 cells. Western blotting and enzyme-linked immunosorbent assay were performed to examine the FXI extracellular secretion profile. Immunofluorescence microscopy was used to investigate the subcellular localization of the rFXI mutant. Results: We identified a novel homozygous frameshift mutation in F11 [c.1788dupC (p.E597Rfs*65)], resulting in a unique and extended carboxyl-terminal (C-terminal) structure in FXI. Although rFXI-E597Rfs*65 was intracellularly synthesized, its extracellular secretion was markedly reduced. Subcellular localization analysis revealed that rFXI-E597Rfs*65 was abnormally retained in the endoplasmic reticulum (ER). We generated a series of C-terminal–truncated rFXI mutants to further investigate the role of the C-terminal region in FXI secretion. Serial rFXI experiments revealed that a threonine at position 622, the fourth residue from the C-terminus, was essential for secretion. Notably, Thr622 engages in the formation of an α-helix motif, indicating the importance of the C-terminal α-helix in FXI intracellular behavior and secretion. Conclusion: FXI E597Rfs*65 results in the pathogenesis of a severe secretory defect resulting from aberrant ER-to-Golgi trafficking caused by the lack of a C-terminal α-helix motif. This study demonstrates the impact of the C-terminal structure, especially the α-helix motif, on FXI secretion.

    DOI: 10.1111/jth.15242

    Web of Science

    Scopus

    PubMed

  8. Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A Reviewed International journal

    Suzuki Atsuo, Suzuki Nobuaki, Kanematsu Takeshi, Okamoto Shuichi, Tamura Shogo, Kikuchi Ryosuke, Katsumi Akira, Kiyoi Hitoshi, Kojima Tetsuhito, Matsushita Tadashi

    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY   Vol. 43 ( 1 ) page: 131 - 138   2021.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:International Journal of Laboratory Hematology  

    Introduction: Factor VIII activity (FVIII:C) is measured by one-stage clotting assay (OSA) or chromogenic substrate assay (CSA). Significant differences in FVIII:C between OSA (FVIII:C1st) and CSA (FVIII:CChr) are described as assay discrepancy in nonsevere haemophilia A (HA). A large number of reagent combinations (APTT reagent and FVIII-deficient plasma) are used for OSA, but the impact of variations in reagent combinations on assay discrepancy has not been fully characterized. Aim: To clarify the variations in FVIII:C1st/FVIII:CChr ratios according to OSA reagent combination in HA subjects with/without assay discrepancy. Methods: Thirty-nine patients previously diagnosed with nonsevere HA were enrolled, and their FVIII genes were investigated and FVIII:C levels were assessed by a single CSA reagent and 11 OSA reagent combinations. Receiver operating characteristic (ROC) curve analysis was used to predict possible cut-off values of the FVIII:C1st/FVIII:CChr ratio to define FVIII assay discrepancy for each reagent combination. Results: Patients were categorized into nondiscrepant (n = 25), discrepant (n = 5) and unclassified (n = 9) groups according to their genotypes and information in the database. The FVIII:C1st/FVIII:CChr ratio in nondiscrepant HA varied widely, depending on the APTT reagents and FVIII-deficient plasma used. The ratio in discrepant HA patients differed with respect to their genotype and the reagent combination used. ROC curve analyses revealed that cut-off values to distinguish the assay discrepancy differed depending on the reagents used, but revealed two novel genotype variants, p.Cys573Gly and p.Gly582Arg, associated with FVIII assay discrepancy. Conclusion: Our findings showed that the FVIII:C1st/FVIII:CChr ratio is dependent on the reagent combination used for OSA.

    DOI: 10.1111/ijlh.13335

    Web of Science

    Scopus

    PubMed

  9. Myh9 R702C is associated with erythroid abnormality with splenomegaly in mice Reviewed International journal

    Kanematsu Takeshi, Suzuki Nobuaki, Tamura Shogo, Suzuki Atsuo, Ishikawa Yuichi, Katsumi Akira, Kiyoi Hitoshi, Saito Hidehiko, Kunishima Shinji, Kojima Tetsuhito, Matsushita Tadashi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 83 ( 1 ) page: 75 - 86   2021.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Nagoya Journal of Medical Science  

    MYH9 disorders are characterized by giant platelets, thrombocytopenia, and Döhle body-like cytoplasmic inclusion bodies in granulocytes. However, whether these disorders cause any changes in erythroid cells has yet to be determined. This study analyzed the influence of Myh9 R702C, as one of the most commonly detected MYH9 disorders, on erythroid cells in a mouse model. Knock-in mice expressing Myh9 R702C mutation either systemically or specific to hematological cells (R702C and R702C vav1 mice, respectively) were used in this study. Both displayed lower hemoglobin and higher erythropoietin levels than wild-type (WT) mice, along with significant splenomegaly. Flow cytometric analysis revealed erythroblasts present at a higher rate than WT mice in the spleen. However, no obvious abnormalities were seen in erythroid differentiation from megakaryocyte/erythroid progenitor to erythrocyte. Cell culture assay by fetal liver and colony assay also showed normal progression of erythroid differentiation from erythroid burst-forming unit to red blood cell. In conclusion, R702C and R702C vav1 mice displayed erythroid abnormality with splenomegaly. However, erythroid differentiation showed no obvious abnormality. Further research is required to elucidate the underlying mechanisms.

    DOI: 10.18999/nagjms.83.1.75

    Web of Science

    Scopus

    PubMed

  10. Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma patients with haemophilia Reviewed International journal

    Yamamoto Takafumi, Imai Norihiro, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Okamoto Shuichi, Kanematsu Takeshi, Suzuki Nobuaki, Matsushita Tadashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

    HAEMOPHILIA   Vol. 27 ( 1 ) page: 100 - 107   2021.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Haemophilia  

    Haemophilia is an X-linked inherited bleeding disorder caused by coagulation factor deficiency. Hepatocellular carcinoma (HCC) is a major complication associated with the disease. No study thus far has investigated the safety and efficacy of percutaneous radiofrequency ablation (RFA) for HCC in patients with haemophilia. Aim: This study aimed to evaluate the safety and efficacy of RFA for HCC in haemophilia patients. Methods: From July 2008 to June 2019, 217 patients with HCC underwent 300 RFA sessions. Of these, 18 sessions were performed in ten haemophilia patients (H group) and 282 in 207 non-haemophilia patients (NH group). The patients' characteristics, incidence of haemorrhagic complications and rates of local tumour recurrence were compared between the groups. Results: A majority of the haemophilia patients received clotting factor concentrate replacement therapy before and after RFA treatment, with the aim of reaching a plasma clotting factor level of higher than 60%–80%. Twelve haemorrhagic complications were observed in the NH group (4.2%; 12/282). Major bleeding requiring control procedures was observed in two patients and minor bleeding with careful observation was noted in ten patients. No bleeding complications were observed in the H group (0/18). There were no significant differences in the 5-year local tumour recurrence rates after RFA treatment between the groups (35.0% in the H group and 32.1% in the NH group). Conclusion: RFA could be an effective and a safe method for HCC treatment in patients with haemophilia.

    DOI: 10.1111/hae.14220

    Web of Science

    Scopus

    PubMed

  11. Bursitis, Bacteremia, and Disseminated Infection of <i>Mycobacteroides</i> (<i>Mycobacterium</i>) <i>abscessus</i> subsp. <i>massiliense</i> International journal

    Oka Keisuke, Morioka Hiroshi, Eguchi Motoki, Sato Yoshitaka, Tetsuka Nobuyuki, Iguchi Mitsutaka, Kanematsu Takeshi, Fukano Hanako, Hoshino Yoshihiko, Kiyoi Hitoshi, Yagi Tetsuya

    Internal Medicine   Vol. 60 ( 18 ) page: 3041 - 3045   2021

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    <p>We herein report a 59-year-old woman with a 2-year history of chronic bursitis of the hand who took 50 mg/day prednisolone for several autoimmune diseases. <i>Mycobacteroides</i> <i>abscessus</i> subsp. <i>massiliense</i> was isolated from the abscess and blood culture. Combination therapy (imipenem/cilastatin, amikacin, and clarithromycin) was administered for a month. Two months later, <i>M. massiliense</i> was detected from a blood culture again, and disseminated lesions were found. Clarithromycin and sitafloxacin were administered following eight weeks of the same regimen. Six months after the diagnosis, <i>M. massiliense</i> was isolated from a blood culture, and she expired due to multiple organ failure. </p>

    DOI: 10.2169/internalmedicine.6189-20

    Web of Science

    Scopus

    PubMed

    CiNii Research

  12. Aberrant X chromosomal rearrangement through multi-step template switching during sister chromatid formation in a patient with severe hemophilia A Reviewed International journal

    Tokoro Mahiru, Tamura Shogo, Suzuki Nobuaki, Kakihara Misaki, Hattori Yuna, Odaira Koya, Suzuki Sachiko, Takagi Akira, Katsumi Akira, Hayakawa Fumihiko, Okamoto Shuichi, Suzuki Atsuo, Kanematsu Takeshi, Matsushita Tadashi, Kojima Tetsuhito

    MOLECULAR GENETICS & GENOMIC MEDICINE   Vol. 8 ( 9 ) page: e1390   2020.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Molecular Genetics and Genomic Medicine  

    Background: Hemophilia A (HA) is an X-linked recessive bleeding disorder caused by pathogenic variants of the coagulation factor VIII gene (F8). Half of the patients with severe HA have a recurrent inversion in the X chromosome, that is, F8 intron 22 or intron 1 inversion. Here, we characterized an abnormal F8 due to atypical complex X chromosome rearrangements in a Japanese patient with severe HA. Methods: Recurrent F8 inversions were tested with inverse shifting-PCR. The genomic structure was investigated using PCR-based direct sequencing or quantitative PCR. Results: The proband's X chromosome had a 119.5 kb insertion, a reverse duplex of an extragenic sequence on the F8 telomere region into the F8 intron 1 with two breakpoints. The telomeric breakpoint was a joining from the F8 intron 1 to the inverted FUNDC2 via a two-base microhomology, and the centromeric breakpoint was a recombination between F8 intron 1 homologous sequences. The rearrangement mechanism was suggested as a multi-step rearrangement with template switching such as fork stalling and template switching (FoSTeS)/microhomology-mediated break-induced replication (MMBIR) and/or homologous sequence-associated recombination during a sister chromatid formation. Conclusion: We identified the aberrant X chromosome with a split F8 due to a multi-step rearrangement in a patient with severe HA.

    DOI: 10.1002/mgg3.1390

    Web of Science

    Scopus

    PubMed

  13. Higher FVIII:C measured by chromogenic substrate assay than by one-stage assay is associated with silent hemophilic arthropathy Reviewed International journal

    Ogawa Mika, Suzuki Nobuaki, Takahashi Nobunori, Tamura Shogo, Suzuki Atsuo, Suzuki Sachiko, Hattori Yuua, Kakihara Misaki, Kanematsu Takeshi, Kojima Toshihisa, Katsumi Akira, Hayakawa Fumihiko, Kojima Tetsuhito, Ishiguro Naoki, Kiyoi Hitoshi, Matsushita Tadashi

    THROMBOSIS RESEARCH   Vol. 188   page: 103 - 105   2020.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Thrombosis Research  

    DOI: 10.1016/j.thromres.2020.01.003

    Web of Science

    Scopus

    PubMed

  14. Lupus anticoagulant-hypoprothrombinemia syndrome associated with follicular lymphoma Reviewed International journal

    KOYAMA Daisuke, HANAJIRI Ryo, KANEMATSU Takeshi, ITO Rie, YAMAMOTO Satomi, IMOTO Naoto, SUZUKI Nobuaki, KURAHASHI Shingo, SUGIURA Isamu

    Rinsho Ketsueki   Vol. 61 ( 7 ) page: 745 - 749   2020

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Hematology  

    <p>A 56-year-old woman was referred to our hospital with symptoms of swelling, purpura, and pain in her limbs. Prior to referral, bleeding in her limbs had spontaneously appeared and disappeared several times. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were prolonged, and the factor II level was 17%. The plasma-mixing test indicated lupus anticoagulant (LA), which was confirmed using aPTT-LA and dilute Russell's viper venom time (dRVVT). Therefore, she was diagnosed with lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS). During screening for underlying disorders, chest computed tomography (CT) revealed a retrosternal mass. Biopsy was not performed because the administration of freshly frozen plasma failed to correct her coagulopathy. Prednisolone (PSL) treatment (1 mg/kg) was initiated, which normalized the coagulation tests. The retrosternal mass also disappeared. PSL was tapered without LAHPS recurrence; however, the follow-up CT revealed systemic lymphadenopathy. Follicular lymphoma was diagnosed using lymph-node biopsy. Considering the subsequent LAHPS recurrence, six cycles of bendamustine + rituximab were administered. Complete response with no LAHPS recurrence was observed at the time of drafting this report. LAHPS is rare and distinct from antiphospholipid syndrome because it can cause severe bleeding. Underlying disorders should be evaluated in cases of LAHPS.</p>

    DOI: 10.11406/rinketsu.61.745

    PubMed

    CiNii Research

  15. Performance Evaluation of INNOVANCE<sup>®</sup> VWF Ac Assay employing recombinant glycoprotein Ib mutant International journal

    Suzuki Atsuo, Suzuki Nobuaki, Kanematsu Takeshi, Okamoto Shuichi, Tamura Shogo, Shinohara Sho, Arai Nobuo, Kikuchi Ryosuke, Ando Yoshitaka, Kojima Tetsuhito, Matsushita Tadashi

    Japanese Journal of Thrombosis and Hemostasis   Vol. 31 ( 4 ) page: 409 - 419   2020

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society on Thrombosis and Hemostasis  

    <p>The measurement of von Willebrand factor (VWF) activity and antigen (Ag) are required to diagnose von Willebrand disease (VWD). In Japan, ristocetin cofactor activity of VWF (VWF:RCo) has been used in a clinical setting. INNOVANCE<sup>®</sup> VWF Ac Assay is based on latex immunoagglutination and measures VWF:GPIbM activity, which employ recombinant glycoprotein Ib carrying two gain-of-function mutation. However, it has not been introduced in Japan yet. Here, we evaluated the performance of INNOVANCE<sup>®</sup> VWF Ac Assay in CS-5100 autoanalyzer. The results showed that within-run and between-day precision were the CVs of <3% and <2%, respectively. We observed a good dilution linearity and a superior limit of detection compared with VWF:RCo. The VWF:GPIbM assay was not affected by interference substances such as bilirubin, hemolytic hemoglobin and chyle, and also by unfractionated heparin (<10 IU/mL). The correlations of VWF:GPIbM versus VWF:RCo or VWF:Ag were excellent in normal plasma. In plasma from patients with VWD, VWF:GPIbM activity was also correlated with VWF:RCo. Taken together, INNOVANCE<sup>®</sup> VWF Ac Assay showed a remarkable performance and it would be expected the future introduction in Japan.</p>

    DOI: 10.2491/jjsth.31.409

    CiNii Research

  16. Performance evaluation of Revohem((TM)) FVIII chromogenic and Revohem((TM)) FIX chromogenic in the CS-5100 autoanalyser Reviewed International journal

    Suzuki Atsuo, Suzuki Nobuaki, Kanematsu Takeshi, Shinohara Sho, Arai Nobuo, Kikuchi Ryosuke, Matsushita Tadashi

    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY   Vol. 41 ( 5 ) page: 664 - 670   2019.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:International Journal of Laboratory Hematology  

    Introduction: Chromogenic substrate assay (CSA) reagents Revohem™ FVIII and Revohem™ FIX are now available as in vitro diagnostic reagents for autoanalysers in Japan. In this study, we evaluated the performance of these reagents in the CS-5100 automated coagulation analyser. Methods: We assessed within-run and between-day imprecision, on-board stability and frozen-storage stability of Revohem FVIII and FIX. Sensitivity to lupus anticoagulant (LA) was examined using LA-positive patient plasma. Correlations were analysed using plasma samples from normal individuals and patients with haemophilia A (HA) or B (HB) or von Willebrand disease (VWD). Results: Imprecision was <2% for Revohem FVIII and <6.5% for Revohem FIX. On-board storage of Revohem FVIII resulted in a <10% decrease in FVIII levels from baseline at 24 hours, whereas Revohem FIX showed a >10% decrease at 8 hours. Revohem FVIII showed good stability while frozen for 22 days. Although Revohem FIX showed degradation due to freeze-thawing, a new calibration improved stability up to 22 days. Interference from LA was not observed with Revohem FVIII or FIX. The FVIII CSA-CSA correlation was excellent in normal (r = 0.9924), HA (r = 0.9945) and VWD (r = 0.9914). The FVIII CSA-OSA correlation was good in normal (r = 0.8468) and excellent in HA (r = 0.975) and VWD (r = 0.9936). The FIX CSA-OSA correlation was fair in normal (r = 0.4791) and excellent in HB (r = 0.9501). Conclusion: Revohem FVIII and FIX both showed excellent performance in the CS-5100 analyser. These reagents could be useful in routine laboratory testing for diagnosing and treating haemophilia.

    DOI: 10.1111/ijlh.13083

    Web of Science

    Scopus

    PubMed

  17. Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors Reviewed International journal

    Shuichi Okamoto, Nobuaki Suzuki, Atsuo Suzuki, Sachiko Suzuki, Shogo Tamura, Mochihito Suzuki, Nobunori Takahashi, Toshihisa Kojima, Takeshi Kanematsu, Tetsuhito Kojima, Hitoshi Kiyoi, Naoki Ishiguro, Tadashi Matsushita

    TH Open   Vol. 3 ( 4 ) page: e364 - e366   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1055/s-0039-3401001

    PubMed

  18. Apparent synonymous mutation F9 c.87A > G causes secretion failure by in-frame mutation with aberrant splicing Reviewed International journal

    Odaira Koya, Tamura Shogo, Suzuki Nobuaki, Kakihara Misaki, Hattori Yuna, Tokoro Mahiru, Suzuki Sachiko, Takagi Akira, Katsumi Akira, Hayakawa Fumihiko, Okamoto Shuichi, Suzuki Atsuo, Kanematsu Takeshi, Matsushita Tadashi, Kojima Tetsuhito

    THROMBOSIS RESEARCH   Vol. 179   page: 95 - 103   2019.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Thrombosis Research  

    Introduction: Hemophilia B is an X-linked recessive bleeding disorder caused by coagulation factor IX (FIX) gene (F9) mutations. Several F9 synonymous mutations have been known to cause hemophilia B; however, the deleterious mechanisms underlying the development of hemophilia B have not been completely understood. To elucidate the molecular pathogenesis causing hemophilia B, we investigated the synonymous F9 mutation: c.87A>G, p.(Thr29=). Materials and methods: The influence of F9 c.87A>G on mRNA splicing was analyzed by exon-trap assay and in silico prediction. We prepared FIX expression vectors using mutant F9 cDNA and transfected HepG2 cells to investigate intracellular transport and extracellular secretion of FIX. Intracellular kinetics of the expressed FIX was examined by treatment with the proteasome inhibitor MG132. Results: Exon-trap analysis revealed that F9 c.87A>G resulted in almost (99.1%) aberrant splicing (r.83_88del). In silico analysis predicted that F9 c.87A>G influenced the splicing pattern by generating an available aberrant 5′ splice site. The aberrant F9 mRNA (r.83_88del) was translated to a mutant FIX p.Cys28_Val30delinsPhe with an in-frame mutation at the signal peptide cleavage site. Simultaneously, a small amount (0.9%) of mutant F9 r.87A>G translating into WT FIX p.Thr29 = was also observed. The mutant FIX was abnormally retained in the endoplasmic reticulum (ER) and was not extracellularly secreted. It appeared to be intracellularly degraded via proteasome-dependent degradation machinery. Conclusion: F9 c.87A>G was found to cause abnormal mRNA splicing, r.83_88del, and produce the mutant FIX p.Cys28_Val30delinsPhe. The mutant FIX is an abnormal protein with extracellular secretory defects and is intracellularly eliminated via proteasome-dependent ER-associated degradation.

    DOI: 10.1016/j.thromres.2019.04.022

    Web of Science

    Scopus

    PubMed

  19. Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: First multicentre study in Asia Reviewed International journal

    Nagao Azusa, Suzuki Nobuaki, Takedani Hideyuki, Yamasaki Naoya, Chikasawa Yushi, Sawada Akihiro, Kanematsu Takeshi, Nojima Masanori, Higasa Satoshi, Amano Kagehiro, Fukutake Katsuyuki, Fujii Teruhisa, Matsushita Tadashi, Suzuki Takashi

    HAEMOPHILIA   Vol. 25 ( 4 ) page: E223 - E230   2019.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Haemophilia  

    Introduction: With the increasing life expectancy of patients with haemophilia (PWH), the number of PWH with age-related comorbidities, such as ischaemic events, is increasing. Aim: We conducted this multicentre observational study to identify the risk factors for major ischaemic events in PWH. Methods: This study was the first multicentre observational study, conducted with the participation of five haemophilia treatment centres in Japan, conducted in ≥30-year-old adult PWH. The latest data recorded in the medical charts between 1 January and 31 December 2016 were reviewed. Healthcare data collected from the National Health and Nutrition Survey were used as the control data. Results: Data of a total of 711 patients were collected. Only two PWH (0.3%) had a history of ischaemic events. Age-adjusted analysis indicated that the prevalence of hypertension defined as a blood pressure of 140/90 mm Hg or over was similar in the PWH to that in the males of the general population. However, when hypertension was defined more strictly (≥130/85 mm Hg), the prevalence was significantly lower in PWH than in the general male population. The hypertension in PWH was associated with the age, BMI, CKD, HIV infection and inhibitors. In particular, the odds ratio for the presence of inhibitors was high (odds ratio = 7.529). Conclusion: Whether the present results can be attributed to Japanese ethnicity or to the presence of haemophilia per se remains uncertain. We propose to initiate a prospective study for further investigation.

    DOI: 10.1111/hae.13749

    Web of Science

    Scopus

    PubMed

  20. Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study) (vol 109, pg 409, 2019) Reviewed International journal

    Murakami Hirokazu, Kasamatsu Tetsuhiro, Murakami Jun, Kiguchi Toru, Kanematsu Takeshi, Ogawa Daisuke, Takamatsu Hiroyuki, Handa Hiroshi, Ozaki Shuji, Miki Hirokazu, Takahashi Takeshi, Takeo Takaaki, Yamauchi Tatsuya, Morishita Takanobu, Kosugi Hiroshi, Shimizu Kazuyuki

    INTERNATIONAL JOURNAL OF HEMATOLOGY   Vol. 110 ( 1 ) page: 125 - 126   2019.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:International Journal of Hematology  

    The authors would like to correct the errors in the publication of the original article. The correction details are given below.

    DOI: 10.1007/s12185-019-02663-5

    Web of Science

    Scopus

    PubMed

  21. Molecular basis of SERPINC1 mutations in Japanese patients with antithrombin deficiency Reviewed International journal

    Tamura Shogo, Hashimoto Erika, Suzuki Nobuaki, Kakihara Misaki, Odaira Koya, Hattori Yuna, Tokoro Mahiru, Suzuki Sachiko, Takagi Akira, Katsumi Akira, Hayakawa Fumihiko, Suzuki Atsuo, Okamoto Shuichi, Kanematsu Takeshi, Matsushita Tadashi, Kojima Tetsuhito

    THROMBOSIS RESEARCH   Vol. 178   page: 159 - 170   2019.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Thrombosis Research  

    Background: Congenital antithrombin (AT) deficiency, which arises from various SERPINC1 defects, is an autosomal-dominant thrombophilic disorder associated with a high risk of recurrent venous thromboembolism. Patients/methods: We investigated SERPINC1 defects in Japanese patients with congenital AT deficiency who developed venous thromboembolism or had a family history of deep vein thrombosis. We analyzed the full DNA sequences of SERPINC1 exons and exon-intron junctions by PCR-mediated direct sequencing. If no mutation was found, multiplex ligation-dependent probe amplification (MLPA) was conducted for the relative quantification of the copy number of all exons in SERPINC1. If splice-site mutations were detected, mRNA splicing abnormalities were further investigated using an in vitro cell-based exontrap assay. Results: We identified 19 different SERPINC1 abnormalities, including 8 novel mutations, in 21 Japanese patients with AT deficiency. These abnormalities were distributed as follows: 9 missense mutations (42.9%), 3 nonsense mutations (14.3%), 1 splice-site mutation (4.8%), 2 small insertions (9.5%), 2 deletion mutations (9.5%) and 4 large deletions (19.0%). Cases with large deletions of SERPINC1 included Alu-mediated gene rearrangements and non-Alu-mediated complex gene rearrangements; the latter could conceivably be explained using the fork stalling and template switching (FoSTeS) model. Conclusions: We identified a variety of SERPINC1 defects in Japanese patients with AT deficiency. The SERPINC1 mutations detected in patients with type I AT deficiency included single nucleotide missense or nonsense mutations, small intragenic insertions or deletions, and large genomic structural deletions. Large deletions of SERPINC1 were caused by various recurrent or non-recurrent complex genomic rearrangement mutations.

    DOI: 10.1016/j.thromres.2019.04.004

    Web of Science

    Scopus

    PubMed

  22. The first case of antithrombin-resistant prothrombin Belgrade mutation in Japanese Reviewed International journal

    Kishimoto Mayuko, Suzuki Nobuaki, Murata Moe, Ogawa Mika, Kanematsu Takeshi, Takagi Akira, Kiyoi Hitoshi, Kojima Tetsuhito, Matsushita Tadashi

    ANNALS OF HEMATOLOGY   Vol. 95 ( 3 ) page: 541 - 542   2016.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Annals of Hematology  

    DOI: 10.1007/s00277-015-2533-6

    Web of Science

    Scopus

    PubMed

  23. A case of MYH9 disorders caused by a novel mutation (p.K74E) Reviewed International journal

    Kanematsu Takeshi, Suzuki Nobuaki, Yoshida Tadao, Kishimoto Mayuko, Aoki Tomohiro, Ogawa Mika, Kagami Yoshitoyo, Kiyoi Hitoshi, Matsushita Tadashi, Kunishima Shinji

    ANNALS OF HEMATOLOGY   Vol. 95 ( 1 ) page: 161 - 163   2016.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Annals of Hematology  

    DOI: 10.1007/s00277-015-2506-9

    Web of Science

    Scopus

    PubMed

  24. 病気のはなし ハイド症候群 Reviewed International journal

    兼松 毅, 松下 正

    検査と技術   Vol. 42 ( 11 ) page: 1188 - 1192   2014.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1543104485

    CiNii Research

  25. Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study).

    Hirokazu Murakami, Tetsuhiro Kasamatsu, Jun Murakami, Toru Kiguchi, Takeshi Kanematsu, Daisuke Ogawa, Hiroyuki Takamatsu, Hiroshi Handa, Shuji Ozaki, Hirokazu Miki, Takeshi Takahashi, Takaaki Takeo, Tatsuya Yamauchi, Takanobu Morishita, Hiroshi Kosugi, Kazuyuki Shimizu

    International journal of hematology   Vol. 109 ( 4 ) page: 409 - 417   2019.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A prospective, multicenter, phase II study was performed to assess the efficacy and safety of thalidomide maintenance therapy at different doses in Japanese multiple myeloma (MM) patients. This study included 34 patients (median age, 74 years) who were previously treated with not more than three prior therapies and whose response status was evaluated as at least stable disease. They were randomized into Group A (no maintenance; 12 patients), Group B (50 mg thalidomide maintenance; 12 patients), and Group C (100 mg thalidomide maintenance; 10 patients), respectively. Thalidomide maintenance therapy resulted in improved depth of response in three cases (13.6%) and sustained response after induction therapy in eight cases (36.4%). Two-year progression-free survival (PFS) was 25.0%, 33.3%, and 77.8% in Groups A, B, and C, respectively, and was significantly higher in Group C than in Group A (p = 0.005). There was no difference in the incidence of hematological or non-hematological adverse events between Groups B and C. The current study demonstrates that maintenance with daily thalidomide at 100 mg, but not 50 mg, improved depth of response and prolonged PFS, and that this treatment was feasible for use in Japanese MM patients.

    DOI: 10.1007/s12185-019-02607-z

    Web of Science

    Scopus

    PubMed

  26. Clot waveform analysis in Clauss fibrinogen assay contributes to classification of fibrinogen disorders International journal

    Suzuki Atsuo, Suzuki Nobuaki, Kanematsu Takeshi, Shinohara Sho, Arai Nobuo, Kikuchi Ryosuke, Matsushita Tadashi

    THROMBOSIS RESEARCH   Vol. 174   page: 98 - 103   2019.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Clauss fibrinogen assay (CFA) is widely used as a screening test to detect fibrinogen disorders. However, CFA alone cannot distinguish quantitative and qualitative defects because it depends on functional fibrinogen activity (Ac), and fibrinogen antigen (Ag) determination is required to classify fibrinogen disorders. OBJECTIVES: To establish a novel approach to classify fibrinogen disorders, we investigated the potential of clot waveform analysis (CWA) of CFA and searched for a surrogate marker for fibrinogen Ag. MATERIALS AND METHODS: We analyzed CWA parameters obtained from CFA using plasma from normal patients (n = 91) and those with fibrinogen disorders (n = 27, including 15 hypofibrinogenemia, 6 dysfibrinogenemia and 6 hypodysfibrinogenemia) with a CS-5100 autoanalyzer. RESULTS: We found that maximum coagulation velocity (Min1) levels were most strongly correlated with fibrinogen Ag in both normal and fibrinogen disorders. Hence, Min1 appeared to function as a surrogate for fibrinogen Ag. Although the Ac/Min1 ratio did not simply reflect the measured Ac/Ag ratio, we found that the Ac/Min1 ratio was significantly higher than normal in hypofibrinogenemia and hypodysfibrinogenemia, but not in dysfibrinogenemia. On the other hand, we could distinguish type II deficiency from type I using estimated fibrinogen Ag (eAg) predicted from Min1. The Ac/eAg ratios of dysfibrinogenemia and hypodysfibrinogenemia were significantly lower than those of normal and hypofibrinogenemia. CONCLUSION: The CWA of CFA could distinguish fibrinogen disorders using a combination of Ac/Min1 and Ac/eAg values. This analysis allows the qualitative detection of fibrinogen disorder easily and represents a novel screening test for fibrinogen disorders.

    DOI: 10.1016/j.thromres.2018.12.018

    Web of Science

    Scopus

    PubMed

  27. Ischemic events are rare among aging patients with hemophilia: Results of a cross-sectional study from at centers treating hemophiliacs in Japan Reviewed

    Suzuki Nobuaki, Takedani Hideyuki, Yamasaki Naoya, Chikasawa Yushi, Sawada Akihiro, Kanematsu Takeshi, Higasa Satoshi, Amano Kagehiro, Fukutake Katsuyuki, Nagao Azusa

    HAEMOPHILIA   Vol. 24   page: 13-14   2018.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  28. Ischemic events are rare among aging patients with hemophilia: Results of a cross-sectional study from at centers treating hemophiliacs in Japan Reviewed International journal

    Suzuki Nobuaki, Takedani Hideyuki, Yamasaki Naoya, Chikasawa Yushi, Sawada Akihiro, Kanematsu Takeshi, Higasa Satoshi, Amano Kagehiro, Fukutake Katsuyuki, Nagao Azusa

    HAEMOPHILIA   Vol. 24   page: 13-14   2018.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  29. Vwf K1362A resulted in failure of protein synthesis in mice.

    Naomi Sanda, Nobuaki Suzuki, Atsuo Suzuki, Takeshi Kanematsu, Mayuko Kishimoto, Hidetoshi Hasuwa, Akira Takagi, Tetsuhito Kojima, Tadashi Matsushita, Shigeo Nakamura

    International journal of hematology   Vol. 107 ( 4 ) page: 428 - 435   2018.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Von Willebrand factor (VWF) is synthesized in megakaryocytes and endothelial cells (ECs) and has two main roles: to carry and protect coagulation factor VIII (FVIII) from degradation by forming VWF-FVIII complex; and to mediate platelet adhesion and aggregation at sites of vascular injury. Previous research using the HEK293 cell line revealed that the VWF K1362 mutation interacted directly with platelet glycoprotein Ib (GPIb). Vwf K1362A knock-in (KI) mice were therefore generated to verify the in vivo function of residue 1362 in binding to platelet GPIb. The Cre-loxP system was employed to introduce the Vwf K1362A mutation systemically in mice. In blood coagulation analysis, the VWF antigen (VWF:Ag) of Lys1362Ala KI homozygous (homo) mice was below the sensitivity of detection by enzyme-linked immunosorbent assay. FVIII activities (FVIII:C) were 47.9 ± 0.3 and 3.3 ± 0.3% (K1362A heterozygous (hetero) and K1362A KI homo mice, respectively) compared to wild-type mice. Immunohistochemical staining analysis revealed that VWF protein did not exist in ECs of K1362A KI homo mice. These results indicated that VWF protein synthesis of K1362A was impaired after transcription in mice. K1362 seems to represent a very important position not only for VWF function, but also for VWF synthesis in mice.

    DOI: 10.1007/s12185-017-2394-y

    Web of Science

    Scopus

    PubMed

  30. Combined deficiency of factors V and VIII by chance coinheritance of parahaemophilia and haemophilia A, but not by mutations of either LMAN1 or MCFD2, in a Japanese family Reviewed International journal

    S. Suzuki, Y. Nakamura, N. Suzuki, T. Yamazaki, Y. Takagi, S. Tamura, A. Takagi, T. Kanematsu, T. Matsushita, T. Kojima

    Haemophilia   Vol. 24 ( 1 ) page: e13 - e16   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Blackwell Publishing Ltd  

    DOI: 10.1111/hae.13360

    Web of Science

    Scopus

  31. その他の凝固因子濃縮製剤の使い方(フィブリノゲン製剤など) International journal

    兼松 毅

    日本血栓止血学会誌   Vol. 29 ( 6 ) page: 744-747 - 747   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:一般社団法人 日本血栓止血学会  

    DOI: 10.2491/jjsth.29.744

    CiNii Research

  32. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study International journal

    N. Suzuki, A. Hirakawa, M. Kishimoto, T. Kanematsu, M. Ogawa, H. Kiyoi, T. Matsushita

    HAEMOPHILIA   Vol. 23 ( 2 ) page: 215 - 221   2017.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:WILEY  

    Background: Continuous infusion (CI) of recombinant FVIII (rFVIII) concentrates has been reported as an effective and safe method to achieve haemostasis during major surgeries or severe bleeding events. For more effective and safer CI, better understanding of in vivo recovery (IVR) and clearance (CL) issues is imperative. Objective: We investigated the following factors affecting IVR and CL using univariate and multivariate regression analyses during 47 CIs in 34 patients: rFVIII concentrate type, haemophilia severity, blood type, the presence of hepatitis C virus (HCV) or human immunodeficiency virus (HIV), age and body mass index (BMI). Results: The mean IVR was 1.64 +/- 0.49 IU dL(-1) per IU kg(-1), and the mean CL during CI was 3.56 +/- 1.57 mL h(-1) kg(-1). The univariate and multivariate regression analyses showed that the CL of octocog alfa was significantly lower than that of rurioctocog alfa (P = 0.043 and 0.0034, respectively). There was a significant difference in BMI in the univariate and multivariate regression analyses (P = 0.0403 and 0.0376, respectively). Conclusions: This study indicated that CL during CI was potentially affected by the type of rFVIII concentrate used and BMI.

    DOI: 10.1111/hae.13082

    Web of Science

    Scopus

▼display all

Presentations 10

  1. Clinical Course and Management of Surgical Emergency in a Severe Hemophilia a Patient Under Weekly Subcutaneous Administration of a Bispecific Antibody to Factors IXa and X (ACE910) International conference

    Kanematsu Takeshi, Suzuki Nobuaki, Sanda Naomi, Ogawa Mika, Kishimoto Mayuko, Suzuki Atsuo, Kiyoi Hitoshi, Kasai Ryu, Matsushita Tadashi

    米国血液学会総会  2015.12.3 

     More details

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  2. Myh9 R702C is associated with altered erythropoiesis in mice

    Takeshi Kanematsu, Nobuaki Suzuki, Atsuo Suzuki, Shogo Tamura, Shuichi Okamoto, Yuichi Ishikawa, Akira Katsumi, Hitoshi Kiyoi, Hidehiko Saito, Shinji Kunishima, Tetsuhito Kojima, Tadashi Matsushita

    2019.10.13 

     More details

    Language:English   Presentation type:Poster presentation  

    Country:Japan  

  3. Continuous infusion of recombinant factor IX Fc fusion protein during major surgery International conference

    Takeshi Kanematsu, Nobuaki Suzuki, Mika Ogawa, Mayuko Kishimoto, Atsuo Suzuki, Hitoshi Kiyoi, Tetsuhito Kojima, Tadashi Matsushita

    XXVI Congress of the International Society on Thrombosis and Haemostasis  2017.7.11 

     More details

    Language:English   Presentation type:Poster presentation  

    Country:Germany  

  4. A case of MYH9 disorders caused by a novel mutation (p.K74E) International conference

    Takeshi KANEMATSU, Nobuaki SUZUKI, Mayuko KISHIMOTO, Tomohiro AOKI, Mika Ogawa, Yoshitoyo KAGAMI, Shinji KUNISHIMA, Hitoshi KIYOI, Tadashi MATSUSHITA

    International Society on Thrombosis and Haemostasis 2015 Congress  2015.6.22 

     More details

    Language:English   Presentation type:Poster presentation  

    Country:Canada  

  5. 21か月の経過で自然寛解した高力価インヒビター保有自己免疫性第V因子欠乏症(AiF5D)の1例

    兼松 毅、鈴木 伸明、岡本 修一、尾崎 司、惣宇利 正善、鈴木 敦夫、田村 彰吾、 早川 文彦、小嶋 哲人、清井 仁、一瀬 白帝、松下 正

    第83回日本血液学会学術集会  2021.9.23  張替 秀郎(東北大学)

     More details

    Event date: 2021.9

    Language:Japanese   Presentation type:Poster presentation  

    Venue:完全Web開催  

  6. 周術期の⽌⾎に難渋した先天性第V因⼦⽋乏症の1例

    兼松 毅、鈴木 伸明、岡本 修一、鈴木 敦夫、田村 彰吾、早川 文彦、小嶋 哲人、清井 仁、松下 正

    第43回日本血栓止血学会学術集会  2021.5.28  浅田 祐士郎

     More details

    Event date: 2021.5

    Language:Japanese  

    Venue:宮崎県   Country:Japan  

  7. Genetic Analysis of Von Willebrand Disease By Using the Exome Sequencing Approach International conference

    Sanda Naomi, Suzuki Nobuaki, Kanematsu Takeshi, Ogawa Mika, Kishimoto Mayuko, Nakamura Shigeo, Matsushita Tadashi

    米国血液学会総会  2015.12.3 

     More details

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  8. 特発性血小板減少性紫斑病の病勢に対し、サイトメガロウイルス再活性化の関与が疑われた2例

    兼松 毅、鈴木 伸明、岡本 修一、鈴木 敦夫、川上 萌、三田 直美、田村 彰吾、小嶋 哲人、清井 仁、松下 正

    日本血栓止血学会学術集会  2019.6.20 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

  9. 当施設における新生児・乳幼児に対するエミシズマブの使用経験

    兼松 毅、鈴木 伸明、岡本 修一、鈴木 敦夫、田村 彰吾、早川 文彦、小嶋 哲人、清井 仁、松下 正

    日本血栓止血学会学術集会  2020.6 

     More details

    Language:Japanese  

  10. ループスアンチコアグラント低プロトロンビン血症症候群(LAHPS)の2例

    兼松 毅、鈴木 伸明、鈴木 敦夫、高木 明、岸本 磨由子、川上(村田) 萌、三田 直美、小山 大輔、小嶋 哲人、清井 仁、松下 正

    日本血栓止血学会学術集会  2018.6.28 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

▼display all

 

Social Contribution 2

  1. 日本血栓止血学会第8回教育セミナー

    Role(s):Lecturer, Organizing member

    2020.11

  2. 日本血栓止血学会第7回教育セミナー

    Role(s):Lecturer, Organizing member

    2019.10